Business, energy, technology, markets and global industry news from Business News Today

Edwards Lifesciences

PharmaDeviceNews Edwards Lifesciences
Representative image: A bioprosthetic aortic valve in a surgical setting highlights the growing focus on long-term heart valve durability as Edwards Lifesciences’ 10-year RESILIA tissue data sharpen the debate over lifetime valve planning in aortic stenosis care.
Medical Devices & Diagnostics

Edwards Lifesciences’ RESILIA data may shift the valve debate, but not without caveats

Valve durability is becoming a lifetime-care question. Edwards Lifesciences’ 10-year RESILIA data raise the stakes for heart teams.

Read More
Edwards Lifesciences advances structural heart care with EVOQUE tricuspid valve replacement
Medical Devices & Diagnostics

Why Edwards Lifesciences is betting on transcatheter replacement to solve tricuspid regurgitation

Find out how transcatheter tricuspid valve replacement is reshaping treatment options for severe regurgitation and what clinicians are watching next.

Read More
Edwards Lifesciences’ SAPIEN M3 is the first transseptal transcatheter mitral valve replacement system to receive U.S. Food and Drug Administration approval.
Medical Devices & Diagnostics

Edwards Lifesciences’ SAPIEN M3 FDA approval marks a turning point for transseptal mitral valve therapy

Edwards Lifesciences’ SAPIEN M3 becomes the first FDA-approved transseptal mitral valve replacement system. Explore how it reshapes TMVR in 2026.

Read More